Multi-Tag Antibody Therapeutics for Pathogen Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production and storage of antibodies are costly and time-consuming, and existing methods require multiple antibodies to target different pathogens, which is inefficient and difficult to scale for large populations, especially with short shelf lives.
Innovation Solution
The use of binding agents with multiple monomers, each with a specific binding region and a shared tag, combined with an anti-tag antibody, allows for efficient targeting of multiple disease agents with a single antibody therapeutic system, enhancing efficacy and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple different therapeutic antibodies are used to target different pathogens, then therapeutic effectiveness is improved, but production cost and complexity increase
Solution Approach 1:
The patent applies universality by designing a single antibody molecule that can bind to multiple different pathogens simultaneously through multiple binding regions. Each binding region targets a different pathogen, allowing one antibody to perform the function of multiple separate antibodies, thereby reducing production complexity while maintaining therapeutic effectiveness
Solution Approach 2:
The patent merges multiple binding regions into a single antibody molecule, combining the functions of multiple antibodies into one unified therapeutic agent. This consolidation reduces the number of separate production processes needed while maintaining the ability to target multiple pathogens
2Adaptability or versatility
If multiple antibodies are stored for different pathogens, then comprehensive protection is improved, but storage requirements and costs increase
Solution Approach 1:
The patent creates a universal antibody that can protect against multiple pathogens simultaneously, eliminating the need to store separate antibody stocks for each pathogen. This single multi-functional antibody provides comprehensive protection while reducing storage requirements
3Reliability
If traditional antibody production methods are used, then antibody functionality is maintained, but production time and cost increase
Solution Approach 1:
The patent segments the antibody production process by using modular binding regions that can be independently designed and assembled. This modular approach allows for more efficient production while maintaining the functional integrity of the final antibody molecule
Solution Approach 2:
The patent changes the production parameters by using a standardized antibody platform with variable binding regions. This allows for rapid production of different antibody variants by changing only the binding region sequences, significantly improving production efficiency while maintaining functionality
Data Source
AI summary
The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has one or more monomers that have a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM). Disease agents include bacteria, bacterial proteins, viruses, viral proteins, cancer cells, and proteins or toxins produced therefrom or from other sources such as snakes, insects, plants, etc. In particular, the present invention includes methods and systems for binding agents having one or more monomers that are specific to neurotoxins that cause botulism.